Annual Cash & Cash Equivalents
$3.85 M
-$9.40 M-70.98%
December 31, 2023
Summary
- As of February 8, 2025, AKTX annual cash & cash equivalents is $3.85 million, with the most recent change of -$9.40 million (-70.98%) on December 31, 2023.
- During the last 3 years, AKTX annual cash & cash equivalents has fallen by -$10.21 million (-72.64%).
- AKTX annual cash & cash equivalents is now -94.42% below its all-time high of $68.92 million, reached on December 31, 2015.
Performance
AKTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.25 M
-$1.93 M-46.23%
September 1, 2024
Summary
- As of February 8, 2025, AKTX quarterly cash and cash equivalents is $2.25 million, with the most recent change of -$1.93 million (-46.23%) on September 1, 2024.
- Over the past year, AKTX quarterly cash and cash equivalents has dropped by -$1.93 million (-46.23%).
- AKTX quarterly cash and cash equivalents is now -97.15% below its all-time high of $78.77 million, reached on September 30, 2015.
Performance
AKTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AKTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -71.0% | -46.2% |
| 3 y3 years | -72.6% | -83.2% |
| 5 y5 years | -29.4% | -64.2% |
AKTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -71.0% | at low | -86.6% | +71.5% |
| 5 y | 5-year | -72.6% | at low | -86.6% | +71.5% |
| alltime | all time | -94.4% | >+9999.0% | -97.2% | +71.5% |
Akari Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.25 M(-46.2%) |
| Jun 2024 | - | $4.18 M(+218.9%) |
| Mar 2024 | - | $1.31 M(-65.9%) |
| Dec 2023 | $3.85 M(-71.0%) | $3.85 M(-46.5%) |
| Jun 2023 | - | $7.18 M(-11.9%) |
| Dec 2022 | $13.25 M(+41.5%) | - |
| Jun 2022 | - | $8.15 M(-51.3%) |
| Mar 2022 | - | $16.72 M(+78.6%) |
| Dec 2021 | $9.36 M(-33.4%) | $9.36 M(-30.1%) |
| Sep 2021 | - | $13.39 M(+253.2%) |
| Jun 2021 | - | $3.79 M(-43.1%) |
| Mar 2021 | - | $6.67 M(-52.6%) |
| Dec 2020 | $14.06 M(+145.2%) | $14.06 M(+14.1%) |
| Sep 2020 | - | $12.32 M(-3.4%) |
| Jun 2020 | - | $12.75 M(+63.0%) |
| Mar 2020 | - | $7.82 M(+36.5%) |
| Dec 2019 | $5.73 M(+5.2%) | $5.73 M(-8.6%) |
| Sep 2019 | - | $6.27 M(+129.1%) |
| Jun 2019 | - | $2.74 M(-55.5%) |
| Mar 2019 | - | $6.15 M(+12.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $5.45 M(-80.6%) | $5.45 M(-45.9%) |
| Sep 2018 | - | $10.07 M(-33.2%) |
| Jun 2018 | - | $15.07 M(-36.6%) |
| Mar 2018 | - | $23.78 M(-15.4%) |
| Dec 2017 | $28.11 M(-17.6%) | $28.11 M(+34.0%) |
| Sep 2017 | - | $20.97 M(-30.4%) |
| Jun 2017 | - | $30.12 M(+20.9%) |
| Mar 2017 | - | $24.92 M(-26.9%) |
| Dec 2016 | $34.10 M(-50.5%) | $34.10 M(+517.1%) |
| Sep 2016 | - | $5.53 M(-42.8%) |
| Jun 2016 | - | $9.66 M(-84.3%) |
| Mar 2016 | - | $61.43 M(-10.9%) |
| Dec 2015 | $68.92 M(+1971.2%) | $68.92 M(-12.5%) |
| Sep 2015 | - | $78.77 M(+2798.2%) |
| Jun 2015 | - | $2.72 M(-32.3%) |
| Mar 2015 | - | $4.02 M(+20.7%) |
| Dec 2014 | $3.33 M(-56.5%) | $3.33 M |
| Dec 2013 | $7.66 M(+593.6%) | - |
| Dec 2012 | $1.10 M(>+9900.0%) | - |
| Dec 2011 | $6000.00 | - |
FAQ
- What is Akari Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akari Therapeutics?
- What is Akari Therapeutics annual cash & cash equivalents year-on-year change?
- What is Akari Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Akari Therapeutics?
- What is Akari Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Akari Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AKTX is $3.85 M
What is the all time high annual cash & cash equivalents for Akari Therapeutics?
Akari Therapeutics all-time high annual cash & cash equivalents is $68.92 M
What is Akari Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AKTX annual cash & cash equivalents has changed by -$9.40 M (-70.98%)
What is Akari Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AKTX is $2.25 M
What is the all time high quarterly cash and cash equivalents for Akari Therapeutics?
Akari Therapeutics all-time high quarterly cash and cash equivalents is $78.77 M
What is Akari Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AKTX quarterly cash and cash equivalents has changed by -$1.93 M (-46.23%)